Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DiaMedica, a biopharmaceutical company, has presented new compelling Type 2 diabetes data from studies of DM-204.
Subscribe to our email newsletter
In an independently conducted study, chronic administration of DM-204 prevented disease progression within an in vivo Type 2 diabetes model.
Reduction in HbA1c is the critical endpoint measurement in receiving regulatory approval for a Type 2 diabetes medication.
Additionally, approximately 70% of Type 2 diabetics are prescribed antihypertensive medication(s) to control blood pressure and prevent heart disease and stroke.
The antihypertensive and cholesterol lowering ability of DM-204 may reduce the need for such medication(s) and furthermore protect Type 2 diabetics from heart disease and stroke complications.
DiaMedica scientific advisory board member and former senior vice president John Amatruda said that these results are very encouraging and provide a strong foundation with which to move DM-204 forward.